Back to dashboard
CommercialCoverageMedium impact

08.02.02b, Ublituximab-xiiy (Briumvi®) for intravenous use

Independence Blue Cross·Neurology, Oncology, Hematology·Pharmacy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Days to comply
—

Summary

A new policy for Ublituximab-xiiy (Briumvi®) intravenous medication has been updated for commercial plans. This is a pharmacy policy change that affects billing and coverage for this specific medication used for multiple sclerosis treatment.

Action Required

Action needed
By October 1, 2025: Review the complete policy details at the provided URL to understand coverage criteria, prior authorization requirements, and billing procedures for Ublituximab-xiiy (Briumvi®). Update billing system and staff training materials accordingly once full policy details are reviewed.

Related policy hubs